Kala Bio (KALA) Interest Coverage Ratio (2016 - 2025)
Kala Bio (KALA) posted Interest Coverage Ratio of 17.78 for Q4 2025, down 136.56% sequentially from 7.52 in Q3 2025, and down 161.69% YoY from 28.83 in Q4 2024.
Kala Bio (KALA) Interest Coverage Ratio (2016 - 2025) Analysis & Trends
Kala Bio has reported Interest Coverage Ratio for 10 years, with the latest figure at 17.78 in Q4 2025.
- Quarterly Interest Coverage Ratio fell 161.69% year-over-year to 17.78 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 11.57 (down 57.8% YoY) and the FY2025 annual result came in at 0.27, up 9.23% from the prior year.
- Interest Coverage Ratio fell to 17.78 in Q4 2025 per KALA's latest filing, from 7.52 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 6.01 in Q3 2023 and troughed at 38.11 in Q4 2022.
- A 5-year average of 11.63 and a median of 9.86 in 2021 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2021 and 2023: Interest Coverage Ratio tumbled 2390.72% in 2021, then soared 82.81% in 2023.
- Over 5 years, Interest Coverage Ratio stood at 21.77 in 2021, then slumped by 75.01% to 38.11 in 2022, then jumped by 82.81% to 6.55 in 2023, then decreased by 3.71% to 6.8 in 2024, then plunged by 161.69% to 17.78 in 2025.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 17.78, 7.52, and 10.2 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.82 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.08 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.42 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 76.86 |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -17.78 |
| Sep 30, 2025 | -7.52 |
| Jun 30, 2025 | -10.20 |
| Mar 31, 2025 | -9.78 |
| Dec 31, 2024 | -6.80 |
| Sep 30, 2024 | -6.76 |
| Jun 30, 2024 | -6.59 |
| Mar 31, 2024 | -8.20 |
| Dec 31, 2023 | -6.55 |
| Sep 30, 2023 | -6.01 |
| Jun 30, 2023 | -6.79 |
| Mar 31, 2023 | -7.93 |
| Dec 31, 2022 | -38.11 |
| Sep 30, 2022 | -10.07 |
| Jun 30, 2022 | -11.77 |
| Mar 31, 2022 | -15.19 |
| Dec 31, 2021 | -21.77 |
| Sep 30, 2021 | -11.75 |
| Jun 30, 2021 | -13.10 |
| Mar 31, 2021 | -9.94 |